XCUR
Exicure, Inc. [XCUR] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
XCUR Stock Summary
Top 10 Correlated ETFs
XCUR
Top 10 Correlated Stocks
XCUR
In the News
XCUR Financial details
Company Rating
-
Market Cap
5.02M
Income
3.07M
Revenue
23.79M
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
7
Optionable
No
Shortable
Yes
Earnings
12 Apr 2024
P/E
1.47
Forward P/E
-
PEG
-0.14
P/S
0.2
P/B
0.54
P/C
-
P/FCF
-0.24
Quick Ratio
1.63
Current Ratio
2.56
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
1.28
EPS next Y
-
EPS next Q
-
EPS this Y
-97.42%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-49.06%
Revenue last 5Y
200.32%
Revenue Q/Q
-
EPS Q/Q
-2.86%
-
-
-
-
SMA20
-8.72%
SMA50
-61.01%
SMA100
169.14%
Inst Own
-
Inst Trans
-
ROA
20%
ROE
40%
ROC
0.2%
Gross Margin
70%
Oper. Margin
12%
Profit Margin
14%
Payout
1%
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
0.365-1.5
52W High
-
52W Low
-
RSI
39.2
Rel Volume
0.04
Avg Volume
225.58K
Volume
9.4K
Perf Week
-17.31%
Perf Month
-7.17%
Perf Quarter
286.88%
Perf Half Y
343.01%
-
-
-
-
Beta
1.225
-
-
Volatility
0.76%, 1.31%
Prev Close
1.3%
Price
8.55
Change
0.71%
Company Profile
- Volume Average 225.58K
- Market Capitalization 5.02M
- Employee 7
- CEO Mr. Paul Kang
- Headquarters Chicago,IL,US
- IPO Date 2018-05-22
-
Website
https://www.exicuretx.com 
Exicure, Inc., a biotechnology company, develops therapies for neurological disorders and hair loss based on its proprietary spherical nucleic acid (SNA) technology. Its lead program candidate includes SCN9A that is in preclinical studies for neuropathic and chronic pain. The company has a collaboration, option, and license agreement with AbbVie Inc. to develop SNA-based treatments for hair loss disorders; and collaboration agreement with Ipsen S.A. to research, develop, and commercialize novel spherical nucleic acids for Huntington's disease and Angelman syndrome. Exicure, Inc. was founded in 2011 and is headquartered in Chicago, Illinois.
